Quick Answer
Black Diamond Therapeutics, Inc. reported Net Income Loss of $22.37 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +132.1% in Net Income Loss from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Net Income Loss has grown by 350.4%.
- Historical annual values: Fiscal year 2025: $22.37 million | Fiscal year 2024: -$69.68 million | Fiscal year 2023: -$82.44 million | Fiscal year 2022: -$91.17 million | Fiscal year 2021: -$125.60 million | Fiscal year 2020: -$67.25 million | Fiscal year 2019: -$35.26 million | Fiscal year 2018: -$8.93 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: